Advancing green chemistry for more sustainable medicines Advancing green chemistry for more sustainable medicines By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Big Little Things in cancer: small things, big impacts Big Little Things in cancer: small things, big impacts Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.
The Unwearable Collection™ Evolution The Unwearable Collection™ Evolution Get ready for the next stage of The Unwearable Collection™
10 tips cat friendly veterinary clinics 10 tips cat friendly veterinary clinics Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
New cancer therapeutics collaboration with 3T Bio New cancer therapeutics collaboration with 3T Bio Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
CAROLINA-CARMELINA-Asia-analysis CAROLINA-CARMELINA-Asia-analysis CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
clinical-collaboration-with-Amgen clinical-collaboration-with-Amgen Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Netherton syndrome (NS) Netherton syndrome (NS) Information on Netherton syndrome (NS), a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences
Ukraine Help: We fly, we bike, we accommodate Ukraine Help: We fly, we bike, we accommodate The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
Sustainable medicines that help minimize environmental impact Sustainable medicines that help minimize environmental impact How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.
The Boehringer Ingelheim Veterinary Scholars Program The Boehringer Ingelheim Veterinary Scholars Program The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Phase 1 start for novel triple agonist obesity treatment Phase 1 start for novel triple agonist obesity treatment Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
EMA filing acceptance and validation for spesolimab EMA filing acceptance and validation for spesolimab The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
1885-1948: Innovative beginnings 1885-1948: Innovative beginnings The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
Spotlight on GPP Spotlight on GPP Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
SPEVIGO approved expanded indications China US SPEVIGO approved expanded indications China US SPEVIGO® approved for expanded indications in China and the US
New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares
Boehringer Ingelheim advances SIRP immune-oncology program Boehringer Ingelheim advances SIRP immune-oncology program Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371